Stem definition | Drug id | CAS RN |
---|---|---|
4289 | 6217-54-5 |
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
None | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pneumonia aspiration | 152.19 | 32.83 | 65 | 3491 | 31540 | 46650966 |
Coma | 114.34 | 32.83 | 65 | 3491 | 58284 | 46624222 |
Gastrooesophageal reflux disease | 104.74 | 32.83 | 67 | 3489 | 74277 | 46608229 |
Pleural thickening | 72.59 | 32.83 | 20 | 3536 | 2575 | 46679931 |
Somnolence | 71.73 | 32.83 | 73 | 3483 | 156448 | 46526058 |
Blood magnesium increased | 69.55 | 32.83 | 20 | 3536 | 3007 | 46679499 |
Presbyacusis | 66.42 | 32.83 | 19 | 3537 | 2803 | 46679703 |
Pleural fibrosis | 66.29 | 32.83 | 20 | 3536 | 3549 | 46678957 |
Deafness neurosensory | 61.75 | 32.83 | 20 | 3536 | 4474 | 46678032 |
Laryngitis | 61.29 | 32.83 | 24 | 3532 | 9292 | 46673214 |
Epigastric discomfort | 57.15 | 32.83 | 20 | 3536 | 5664 | 46676842 |
Muscle spasticity | 53.22 | 32.83 | 23 | 3533 | 11417 | 46671089 |
Immunodeficiency | 50.22 | 32.83 | 23 | 3533 | 13083 | 46669423 |
Respiratory disorder | 46.98 | 32.83 | 28 | 3528 | 27272 | 46655234 |
Cyst | 45.63 | 32.83 | 21 | 3535 | 12079 | 46670427 |
Joint swelling | 41.74 | 32.83 | 57 | 3499 | 166016 | 46516490 |
Ear pain | 41.54 | 32.83 | 24 | 3532 | 22068 | 46660438 |
Bone cyst | 40.27 | 32.83 | 12 | 3544 | 2039 | 46680467 |
Osteopenia | 38.90 | 32.83 | 21 | 3535 | 16940 | 46665566 |
Blood potassium increased | 38.90 | 32.83 | 21 | 3535 | 16946 | 46665560 |
Body temperature increased | 36.39 | 32.83 | 23 | 3533 | 24838 | 46657668 |
Night sweats | 34.46 | 32.83 | 23 | 3533 | 27227 | 46655279 |
Osteosclerosis | 33.92 | 32.83 | 12 | 3544 | 3504 | 46679002 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Coronary artery disease | 38.72 | 31.02 | 17 | 393 | 49695 | 29902373 |
Source | Code | Description |
---|---|---|
CHEBI has role | CHEBI:35610 | cytostatic |
CHEBI has role | CHEBI:50733 | nutritional supplement |
CHEBI has role | CHEBI:75771 | mus musculus metabolite |
CHEBI has role | CHEBI:77746 | h. sapiens metabolites |
CHEBI has role | CHEBI:83146 | daphnia tenebrosa metabolites |
CHEBI has role | CHEBI:84735 | algal metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pregnancy, function | indication | 289908002 | |
Breastfeeding (mother) | indication | 413712001 | |
Prevention of Fetal Neural Tube Defects during Pregnancy | off-label use |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.37 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Free fatty acid receptor 1 | GPCR | AGONIST | EC50 | 6 | IUPHAR | ||||
Aromatase | Enzyme | IC50 | 4.48 | CHEMBL | |||||
Oxoeicosanoid receptor 1 | GPCR | IC50 | 5.70 | CHEMBL | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 5.01 | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 4.82 | CHEMBL | |||||
Transient receptor potential cation channel subfamily A member 1 | Unclassified | ACTIVATOR | EC50 | 4.40 | IUPHAR |
ID | Source |
---|---|
4020132 | VUID |
N0000148111 | NUI |
4020132 | VANDF |
C2348308 | UMLSCUI |
CHEBI:28125 | CHEBI |
F22 | PDB_CHEM_ID |
HXA | PDB_CHEM_ID |
CHEMBL367149 | ChEMBL_ID |
DB03756 | DRUGBANK_ID |
C532150 | MESH_SUPPLEMENTAL_RECORD_UI |
445580 | PUBCHEM_CID |
1051 | IUPHAR_LIGAND_ID |
6428 | INN_ID |
ZAD9OKH9JC | UNII |
1006469 | RXNORM |
002051 | NDDF |
226368001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
CitraNatal Harmony 3.0 | HUMAN PRESCRIPTION DRUG LABEL | 8 | 0178-0796 | CAPSULE, GELATIN COATED | 260 mg | ORAL | unapproved drug other | 10 sections |
CitraNatal Harmony | HUMAN PRESCRIPTION DRUG LABEL | 8 | 0178-0798 | CAPSULE, GELATIN COATED | 260 mg | ORAL | UNULLPPROVED DRUG OTHER | 11 sections |
CitraNatal Harmony | HUMAN PRESCRIPTION DRUG LABEL | 8 | 0178-0799 | CAPSULE, GELATIN COATED | 250 mg | ORAL | Unapproved drug other | 11 sections |
CitraNatal Harmony | HUMAN PRESCRIPTION DRUG LABEL | 8 | 0178-0812 | CAPSULE, GELATIN COATED | 250 mg | ORAL | Unapproved drug other | 11 sections |
CitraNatal Medley | HUMAN PRESCRIPTION DRUG LABEL | 8 | 0178-0896 | CAPSULE, GELATIN COATED | 200 mg | ORAL | unapproved drug other | 10 sections |
Vitafol Ultra | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0642-0093 | CAPSULE, LIQUID FILLED | 200 mg | ORAL | UNULLPPROVED DRUG OTHER | 13 sections |
Vitafol Fe Plus | HUMAN PRESCRIPTION DRUG LABEL | 17 | 0642-7473 | CAPSULE, LIQUID FILLED | 200 mg | ORAL | UNULLPPROVED DRUG OTHER | 14 sections |
TriStart DHA | HUMAN PRESCRIPTION DRUG LABEL | 15 | 15370-250 | CAPSULE, LIQUID FILLED | 200 mg | ORAL | UNULLPPROVED DRUG OTHER | 12 sections |
PNV-DHA | HUMAN PRESCRIPTION DRUG LABEL | 10 | 42192-321 | CAPSULE, GELATIN COATED | 300 mg | ORAL | unapproved drug other | 11 sections |
PNV-DHA | HUMAN PRESCRIPTION DRUG LABEL | 8 | 42192-323 | CAPSULE, GELATIN COATED | 300 mg | ORAL | unapproved drug other | 11 sections |
PNV-Omega | HUMAN PRESCRIPTION DRUG LABEL | 13 | 42192-332 | CAPSULE, GELATIN COATED | 300 mg | ORAL | unapproved drug other | 12 sections |
Prenaissance | HUMAN PRESCRIPTION DRUG LABEL | 9 | 42192-341 | CAPSULE, LIQUID FILLED | 325 mg | ORAL | UNULLPPROVED DRUG OTHER | 10 sections |
Prenaissance Plus | HUMAN PRESCRIPTION DRUG LABEL | 8 | 42192-343 | CAPSULE, LIQUID FILLED | 250 mg | ORAL | UNULLPPROVED DRUG OTHER | 10 sections |
Animi-3 with Vitamin D | HUMAN PRESCRIPTION DRUG LABEL | 8 | 66213-542 | CAPSULE | 250 mg | ORAL | unapproved drug other | 14 sections |
Animi-3 | HUMAN PRESCRIPTION DRUG LABEL | 8 | 66213-543 | CAPSULE | 250 mg | ORAL | unapproved drug other | 14 sections |
TRICARE PRENULLTAL DHA ONE | HUMAN PRESCRIPTION DRUG LABEL | 17 | 67112-401 | CAPSULE, GELATIN COATED | 215 mg | ORAL | unapproved drug other | 12 sections |
TRICARE PRENULLTAL DHA ONE | HUMAN PRESCRIPTION DRUG LABEL | 17 | 67112-401 | CAPSULE, GELATIN COATED | 215 mg | ORAL | unapproved drug other | 12 sections |
TRICARE PRENULLTAL DHA ONE RXMULTIVITAMIN | HUMAN PRESCRIPTION DRUG LABEL | 18 | 67112-402 | CAPSULE, GELATIN COATED | 215 mg | ORAL | unapproved drug other | 11 sections |
PRENULLTE Restore | HUMAN PRESCRIPTION DRUG LABEL | 12 | 75854-308 | CAPSULE, GELATIN COATED | 400 mg | ORAL | unapproved drug other | 13 sections |
PRENULLTE Enhance | HUMAN PRESCRIPTION DRUG LABEL | 12 | 75854-309 | CAPSULE, GELATIN COATED | 400 mg | ORAL | unapproved drug other | 13 sections |
PRENULLTE DHA | HUMAN PRESCRIPTION DRUG LABEL | 10 | 75854-312 | CAPSULE, GELATIN COATED | 300 mg | ORAL | unapproved drug other | 13 sections |
Prenate Essential | HUMAN PRESCRIPTION DRUG LABEL | 14 | 75854-313 | CAPSULE, GELATIN COATED | 300 mg | ORAL | unapproved drug other | 13 sections |
Prenate Mini | HUMAN PRESCRIPTION DRUG LABEL | 15 | 75854-315 | CAPSULE, GELATIN COATED | 350 mg | ORAL | unapproved drug other | 12 sections |